Express Healthcare
Home  »  News  »  IIT Madras develops AI-based algorithm to identify cancer-causing alterations

IIT Madras develops AI-based algorithm to identify cancer-causing alterations

0 135
Read Article

This technique will tackle the complexity and size of DNA-sequencing datasets, and can help in pinpointing key alterations in the genomes of cancer patients, which is difficult using present methodologies

The Indian Institute of Technology (IIT) Madras researchers have developed an Artificial Intelligence (AI)-based mathematical model to identify cancer-causing alterations in cells. The algorithm uses a technique of leveraging DNA composition to pinpoint genetic alterations responsible for cancer progression, a statement from the institute said.

Cancer is caused due to the uncontrolled growth of cells driven mainly by genetic alterations. In recent years, high-throughput DNA sequencing has revolutionised the area of cancer research by enabling the measurement of these alterations. However, due to the complexity and size of these sequencing datasets, pinpointing the exact changes from the genomes of cancer patients is notoriously difficult, it mentioned.

The results have been recently published in the peer-reviewed International Journal Cancers.

Explaining the rationale behind this study, Professor B Ravindran, Head, Robert Bosch Centre for Data Science and AI (RBCDSAI), IIT Madras, said, “One of the major challenges faced by cancer researchers involves the differentiation between the relatively small number of ‘driver’ mutations that enable the cancer cells to grow and the large number of ‘passenger’ mutations that do not have any effect on the progression of the disease.”

The researchers hope that the driver mutations predicted through their mathematical model will ultimately help discover potentially novel drug targets and will advance the notion of prescribing the right drug to the right person at the right time, said the statement.

Elaborating on the need for developing this technique, Dr Karthik Raman, Associate Professor, Department of Biotechnology, Bhupat and Jyoti Mehta School of Biosciences, IIT Madras, said, “In most of the previously published techniques, researchers typically analysed DNA sequences from large groups of cancer patients, comparing sequences from cancer as well as normal cells and determined whether a particular mutation occurred more often in cancer cells than random. However, this ‘frequentist’ approach often missed out on relatively rare driver mutations.”

Highlighting how this algorithm will impact cancer treatment in the days to come, Dr Raman said, “Detecting driver mutations, particularly rare ones, is an exceptionally difficult task, and the development of such methods can ultimately accelerate early diagnoses and the development of personalised therapies.”

According to the statement, in this study, the researchers decided to look at this problem from a different perspective. The main goal was to discover patterns in the DNA sequences – made up of four letters, or bases, A, T, G and C surrounding a particular site of alteration.

It mentioned, “The underlying hypothesis was that these patterns would be unique to individual types of mutations – drivers and passengers, and, therefore, could be modelled mathematically to distinguish between the two classes. Using sophisticated AI techniques, the researchers developed a novel prediction algorithm, NBDriver and tested its performance on several open-source cancer mutation datasets.

Highlighting on the performance of the algorithm, Dr Ravindran added, “Our model could distinguish between well-studied drivers and passenger mutations from cancer genes with an accuracy of 89 per cent. Furthermore, combining the predictions from NBDriver and three other commonly-used driver prediction algorithms resulted in an accuracy of 95 per cent, significantly outperforming existing models.”

Dr Raman added, “Interestingly, NBDriver could accurately identify 85 per cent of the rare driver mutations from patients diagnosed with Glioblastoma Multiforme (GBM), a particularly aggressive type of cancer affecting the brain or spine.”

Leave A Reply

Your email address will not be published.

Attend an exclusive webinar to know more about biomarkers in diagnosis & therapy management of heart failure.
Register Now
close-image
 Introducing Smart Autoinjector: Changing the paradigm of usability, cost & size
Know More?
close-image
Are you looking for ICP-MS which can increase productivity and remove time trap from your analysis?
Know More
close-image